by pixalien | Sep 17, 2020 | General
OncoSpherix was awarded a $399,774 phase 1 SBIR from the NCI in for a project entitled “Arylsulfonamides for the Treatment of Primary and Metastatic Uveal Melanoma”.
by pixalien | Sep 15, 2020 | General
US Patent entitled “Benzhydrol derivatives for the management of conditions related to hypoxia inducible factors” was awarded to Georgia State University Research Foundation and to Emory University. It is included in the portfolio that OncoSpherix licensed from the...
by pixalien | Aug 21, 2020 | General
OncoSpherix selected as a Cade Prize Fibonacci Finalist for Inventors and Entrepreneurs: Since 2010, the Cade Prize has celebrated innovation by identifying, recognizing, and celebrating Florida-based inventors and entrepreneurs at the pre-seed and seed stages. The...
by pixalien | Aug 7, 2020 | General
Dr Margaret Offermann, CEO of OncoSpherix, is among the 8 semi-finalist in the AIM-HI Women’s Venture Competition: The 8 semifinalists were selected from a pool of 47 candidates from 6 countries. “The Women’s Venture Competition is one of the first venture-backed...
by pixalien | May 1, 2020 | General
May, 2020: OncoSpherix’s CEO, Dr. Margaret K. Offermann, served as Keynote Speaker and Session Chairperson in the Agile Falcon 5th Drug Discovery Strategic Summit. Her talk was titled “Discovery and Development of Small Molecule Inhibitors of Hypoxia Inducible Factors...
